# Transforming Growth Factor Beta Signalling in the Development of Muscle Weakness in Pulmonary Arterial Hypertension

> **NCT01847716** · — · TERMINATED · sponsor: **Imperial College London** · enrollment: 33 (actual)

## Conditions studied

- Muscle Weakness
- Pulmonary Arterial Hypertension

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01847716
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2013-10
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 33 (ACTUAL)
- **Why stopped:** numbers recruited to show adequate association but not primary outcome
- **Last updated:** 2018-09-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01847716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01847716, "Transforming Growth Factor Beta Signalling in the Development of Muscle Weakness in Pulmonary Arterial Hypertension". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01847716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*